IMPACT trial, in collaboration with INNODIA
Imcyse, a biopharmaceutical company pioneering the development of specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patients’ treatment in the IMPACT study in Type 1 Diabetes (T1D).